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Objective. To develop an evidence- based guideline for the comprehensive management of osteoarthritis (OA) as a collabora-
tion between the American College of Rheumatology (ACR) and the Arthritis Foundation, updating the 2012 ACR recommenda-
tions for the management of hand, hip, and knee OA.
Methods. We identified clinically relevant population, intervention, comparator, outcomes questions and critical outcomes in 
OA. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of 
available educational, behavioral, psychosocial, physical, mind- body, and pharmacologic therapies for OA. Grading of Recommen-
dations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. A Voting Panel, includ-
ing rheumatologists, an internist, physical and occupational therapists, and patients, achieved consensus on the recommendations.
Results. Based on the available evidence, either strong or conditional recommendations were made for or against the ap-
proaches evaluated. Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are 
overweight or obese, self- efficacy and self- management programs, tai chi, cane use, hand  orthoses for first carpometacarpal 
(CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, 
oral NSAIDs, and intraarticular glucocorticoid injections for knee OA. Conditional recommendations were made for balance exer-
cises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, 
patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical 
NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, du-
loxetine, and tramadol.
Conclusion. This guideline provides direction for clinicians and patients making treatment decisions for the management of 
OA. Clinicians and patients should engage in shared decision- making that accounts for patients’ values, preferences, and comor-
bidities. These recommendations should not be used to limit or deny access to therapies.
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are in-
tended to provide guidance for patterns of practice and not to dictate the care of a particular patient. The ACR considers 
adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their 
application to be made by the clinician in light of each patient’s individual circumstances. Guidelines and recommenda-
tions are intended to promote beneficial or desirable outcomes, but cannot guarantee any specific outcome. Guidelines 
and recommendations developed and endorsed by the ACR are subject to periodic revision, as warranted by the evo-
lution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or 
insurance decisions. These recommendations cannot adequately convey all uncertainties and nuances of patient care.
The American College of Rheumatology is an independent, professional, medical and scientific society that does not 
guarantee, warrant, or endorse any commercial product or service.
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INTRODUCTION
Osteoarthritis (OA) is the most common form of arthritis, 
affecting an estimated 302 million people worldwide (1–5), and is 
a leading cause of disability among older adults. The knees, hips, 
and hands are the most commonly affected appendicular joints. 
OA is characterized by pathology involving the whole joint, includ-
ing cartilage degradation, bone remodeling, osteophyte forma-
tion, and synovial inflammation, leading to pain, stiffness, swelling, 
and loss of normal joint function.
As OA spans decades of a patient’s life, patients with OA 
are likely to be treated with a number of different pharmaceutical 
and nonpharmaceutical interventions, often in combination. This 
report provides recommendations to guide patients and clinicians 
in choosing among the available treatments. Certain principles of 
management apply to all patients with OA (see Comprehensive 
Management of OA below and Figure 1). Some recommendations 
are specific to a particular joint (e.g., hip, knee, patellofemoral joint, 
first carpometacarpal joint [CMC]) or particular patient populations 
(e.g., those with erosive OA).
METHODS
This guideline, from the American College of Rheumatol-
ogy (ACR) and the Arthritis Foundation (AF), follows the ACR 
guideline development process (https ://www.rheum atolo gy.org/ 
Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines ), 
using the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) methodology to rate the quality of the 
available evidence and to develop the recommendations (6). ACR 
policy guided management of conflicts of interest and  disclosures 
(https ://www.rheum atolo gy.org/Pract ice-Quali ty/Clini cal- 
Suppo rt/Clini cal-Pract ice-Guide lines/ Osteo arthr itis). A full de scrip-
tion of the methods is presented in Supplementary Appendix 1  
(on the Arthritis Care & Research web site at http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24131/ abstract).
Briefly, this work involved 5 teams: 1) a Core Leadership 
Team that supervised and coordinated the project and drafted 
the clinical/population, intervention, comparator, outcomes (PICO) 
questions that served as the basis for the evidence report and 
manuscript; 2) a Literature Review Team that completed the liter-
ature screening and data abstraction and produced the Evidence 
Report (Supplementary Appendix 2, http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24131/ abstract); 3) an Expert Panel that 
had input into scoping and clinical/PICO question development; 
4) a Patient Panel; and 5) an interprofessional Voting Panel that 
included rheumatologists, an internist, physical and occupational 
therapists, and patients (Supplementary Appendix 3, http://onlin e 
l ibr ary.wiley.com/doi/10.1002/acr.24131/ abstract).
This guideline included an initial literature review limited to 
English- language publications from inception of the databases 
to October 15, 2017, with updated searches conducted on 
August 1, 2018 and relevant papers included. Studies pub-
lished after August 1, 2018 were not evaluated for this guide-
line. Supplementary Appendix 4 (http://onlin elibr ary.wiley.com/
doi/10.1002/acr.24131/ abstract) shows search terms used and 
databases reviewed, and Supplementary Appendix 5 (http://
onlin elibr ary.wiley.com/doi/10.1002/acr.24131/ abstract) high-
lights the study selection process. The guideline evidence 
base results from our own systematic review of randomized 
This article is published simultaneously in Arthritis & Rheumatology.
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 controlled trials (RCTs), rather than focusing on systematic 
reviews and meta- analyses published by others, as was done 
for the 2012 ACR recommendations for the use of nonpharma-
cologic and pharmacologic therapies in hand, hip, and knee 
OA (7). Systematic reviews of observational studies published 
by others were included if, in the opinion of the Voting Panel, 
they added critical information for the formulation of a recom-
mendation: for example, related to adverse effects that may 
not be seen in shorter- duration RCTs. Subsequent updates of 
this guideline will consider studies included here and new RCTs 
published since completion of the literature review for the cur-
rent  publication.
Although RCTs are considered the gold standard for evalu-
ation, a number of limitations of RCTs proved particularly impor-
tant in the formulation of the final recommendations: possible 
publication bias (favoring publication of positive results), inade-
quate blinding, and inadequate provision of active comparators 
and appropriate sham alternatives. Further, short- duration RCTs 
cannot provide adequate prognostic information when applied 
to a complex disease such as OA, in which pathophysiologic 
processes are slowly progressive over decades.
We focused on management options that are available in the 
US and, for pharmacologic therapies, we additionally focused on 
agents that are available in pharmaceutical- grade formulations, 
thus eliminating most nutraceuticals. We limited our review to the 
English- language literature. We reviewed www.clini caltr ials.gov to 
identify phase 2 and 3 trials that may be far enough along to be 
US Food and Drug Administration (FDA)–approved and available 
by the time this guideline was published.
A hierarchy of outcome measures assessing pain and 
function in OA was developed based on the published literature 
(8,9). This hierarchy is detailed in Supplementary Appendix 1 
(http://onlin elibr ary.wiley.com/doi/10.1002/acr.24131/ abstract).
Using GRADE, a recommendation can be either in favor 
of or against the proposed intervention and either strong or 
conditional (10,11). The strength of the recommendation is 
based on a 70% consensus among the Voting Panel mem-
bers. Much of the evidence proved indirect (did not specifically 
address the PICO question as written) and of low- to- moderate 
quality (12,13). The Voting Panel made strong recommenda-
tions when it inferred compelling evidence of efficacy and that 
benefits clearly outweighed harms and burdens. Thus, a strong 
recommendation means that the Voting Panel was confident 
that the desirable effects of following the recommendation 
outweigh potential undesirable effects (or vice versa), so the 
course of action would apply to all or almost all patients, and 
only a small proportion of patients would not want to follow the 
recommendation.
The Voting Panel made conditional recommendations 
when the quality of the evidence proved low or very low and/
Figure  1. Recommended therapies for the management of 
osteoarthritis (OA). Strongly and conditionally recommended 
approaches to management of hand, knee, and/or hip OA are 
shown. No hierarchy within categories is implied in the figure, with 
the recognition that the various options may be used (and reused) 
at various times during the course of a particular patient’s disease. 
* = Exercise for knee and hip OA could include walking, strengthening, 
neuromuscular training, and aquatic exercise, with no hierarchy 
of one over another. Exercise is associated with better outcomes 
when supervised. ** = Knee brace recommendations: tibiofemoral 
(TF) brace for TF OA (strongly recommended), patellofemoral (PF) 
brace for PF OA (conditionally recommended). *** = Hand orthosis 
recommendations: first carpometacarpal (CMC) joint neoprene 
or rigid orthoses for first CMC joint OA (strongly recommended), 
orthoses for joints of the hand other than the first CMC joint 
(conditionally recommended). RFA = radiofrequency ablation; 
NSAIDs = nonsteroidal antiinflammatory drugs; IA = intraarticular.




























































KOLASINSKI ET AL 152       |
or the balance of benefits versus harms and burdens was suffi-
ciently close that shared decision- making between the patient 
and the clinician would be particularly important. Conditional 
recommendations are those for which the majority of informed 
patients would choose to follow the recommended course of 
action, but some would not (14,15). Thus, conditional recom-
mendations are particularly value- and preference- sensitive 
and always warrant a full shared decision- making approach 
involving a complete and clear explication of benefits, harms, 
and burdens in language and in a context that patients under-
stand (16). Where recommendations are made regarding 
a particular approach, details and references regarding that 
approach can be found in the Evidence Report (Supplemen-
tary Appendix 2, http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24131/ abstract).
RESULTS/RECOMMENDATIONS
Comprehensive management of OA
A comprehensive plan for the management of OA in an 
individual patient may include educational, behavioral, psycho-
social, and physical interventions, as well as topical, oral, and 
intraarticular medications. Recommendations assume appropri-
ate appli cation of physical, psychological, and/or pharmacologic 
therapies by an appropriate provider. Goals of management and 
principles for implementing those goals have broad applicability 
across patients. However, for some patients at some time points, 
a single physical, psychosocial, mind- body, or pharmacologic 
intervention may be adequate to control symptoms; for others, 
multiple interventions may be used in sequence or in combina-
tion. Which interventions and the order in which interventions 
are used will vary among patients. An overview of a general 
approach to management of OA is outlined in Figure 1 for rec-
ommended options, but no specific hierarchy of one option over 
another is implied other than on the basis of strength of the rec-
ommendation. Figure 2 summarizes the approaches that were 
not recommended.
Treatment decisions should take the personal beliefs and 
preferences of the patient, as well as the patient’s medical sta-
tus, into consideration. This guideline applies to patients with 
OA with no specific contraindications to the recommended 
therapies. However, each patient should be assessed for the 
presence of medical conditions, such as hypertension, cardi-
ovascular disease, heart failure, gastrointestinal bleeding risk, 
chronic kidney disease, or other comorbidities, that might have 
an impact on their risk of side effects from certain pharmacologic 
agents, as well as injuries, disease severity, surgical history, and 
access to and  availability of services (transportation, distance, 
ability to take time off work, cost, insurance coverage) that might 
have an impact on the choice of physical, psychological, and 
mind- body approaches. It is assumed that such an assessment 
Figure 2. Therapies recommended against (physical, psychosocial, and mind- body approaches [A] and pharmacologic approaches [B]) 
in the management of hand, knee, and/or hip osteoarthritis. No hierarchy within categories is implied in the figure. TENS = transcutaneous 
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will be performed prior to finalization of an individual treatment 
plan. When choosing among pharmacologic therapies, man-
agement should begin with treatments with the least systemic 
exposure or toxicity.
Patients may experience a variety of additional symptoms 
as a result of the pain and functional limitations arising from 
OA and/or comorbidities. These include mood disorders, such 
as depression and anxiety, altered sleep, chronic widespread 
pain, and impaired coping skills. The Patient Panel noted that 
the broader impact of OA on these comorbidities is of particular 
importance when choosing among treatment options and best 
addressed by a multimodal treatment plan, rather than one that 
is limited to the prescription of a single medication. Measures 
aimed at improving mood, reducing stress, addressing insom-
nia, managing weight, and enhancing fitness may improve the 
patient’s overall well- being and OA treatment success. Indeed, 
interventions that have proven beneficial in the management of 
chronic pain may prove useful in OA (17) even when data specific 
to patients with OA are limited.
Unless otherwise specified, recommendations regarding 
physical, psychosocial, and mind- body approaches assume that 
the patient will be adding the intervention to usual care. For the 
purposes of this guideline, usual care includes the use of maxi-
mally recommended or safely tolerated doses of over- the coun-
ter oral nonsteroidal antiinflammatory drugs (NSAIDs) and/or 
acetaminophen, as has generally been explicitly permitted in clini-
cal trials of nonpharmacologic interventions.
Physical, psychosocial, and mind- body approaches 
(Table 1)
During the GRADE analysis, clinical trials involving physical 
modalities and mind- body approaches were often designated 
as yielding low- quality evidence because blinding with regard to 
the active treatment was not always possible. This contributed 
to a preponderance of conditional recommendations for physical 
modalities and mind- body approaches. The delivery of instruction 
by physical and occupational therapists is helpful, and often essen-
tial, for the appropriate initiation and maintenance of exercise as 
a part of OA management. In addition to exercise, physical and 
occupational therapists often incorporate self- efficacy and self- 
management training, thermal therapies, and instruction in use of 
and fitting of splints and braces in their practices. Most patients 
with OA are likely to experience benefit from referral to physical 
therapy and/or occupational therapy at various times during the 
course of their disease.
Exercise is strongly recommended for patients with 
knee, hip, and/or hand OA.
Though exercise is strongly recommended for all OA patients, 
there is considerably more evidence for the use of exercise in the 
treatment of knee and hip OA than for hand OA, and the vari-
ety of exercise options studied is far greater. While patients and 
 providers seek recommendations on the “best” exercise and the 
ideal dosage (duration, intensity, and frequency), current evidence 
Table  1. Recommendations for physical, psychosocial, and mind- body approaches for the management of oste-
oarthritis of the hand, knee, and hip
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is insufficient to recommend specific exercise prescriptions. 
Broad recommendations suggesting one form of exercise over 
another are based largely on expert opinion. A substantial body 
of literature (see Evidence Report, Supplementary Appendix 2 
[http://onlin elibr ary.wiley.com/doi/10.1002/acr.24131/ abstract]) 
supports a wide range of appropriate exercise options and sug-
gests that the vast majority of OA patients can participate in, 
and benefit from with regard to pain and function, some form 
of exercise. Exercise recommendations to patients should focus 
on the patient’s preferences and access, both of which may be 
important barriers to participation. If a patient does not find a cer-
tain form of exercise acceptable or cannot afford to participate or 
arrange transportation to participate, he or she is not likely to get 
any benefit from the suggestion to pursue that exercise.
In the majority of studies that assessed the role of aerobic 
exercise in the management of OA, walking was the most com-
mon form of exercise evaluated, either on a treadmill or as super-
vised, community- based, indoor fitness walking. Other studies 
used supervised group cycling on stationary bicycles. Strengthe-
ning exercises have included the use of isokinetic weight machines, 
resistance exercise training with and without props such as elastic 
bands, and isometric exercise. Neuromuscular training has been 
developed to address muscle weakness, reduced sensorimotor 
control, and functional instability specifically seen with knee OA, with 
a series of dynamic maneuvers of increased complexity. Aquatic 
exercise often encompasses aspects of aerobic fitness exercises 
and exercises for enhancing joint range of motion, in a low- impact 
environment.
A specific hierarchy of these various forms of exercise could 
not be discerned from the literature. Patient participants on the 
Patient and Voting Panels raised the concern that patients who 
are in pain might be hesitant to participate in exercise. There is 
no uniformly accepted level of pain at which a patient should or 
should not exercise, and a common- sense approach of shared 
decision- making between the treating clinician and the patient 
regarding when to initiate an exercise program is advisable. How-
ever, clinical trials of exercise for OA include patients with pain and 
functional limitations due to OA, and improvements in OA- specific 
outcomes have been demonstrated; thus, results are likely to be 
generalizable to most patients with pain due to OA.
Although there is currently insufficient evidence to recom-
mend one form of exercise over another, patients will likely ben-
efit from advice that is as specific as possible, rather than simple 
encouragement to exercise. Given the wide range of evidence- 
based exercise interventions shown to effectively improve pain 
and function in OA, all patients should be encouraged to consider 
some form of exercise as a central part of their treatment plan. 
Individual preferences, access, and affordability are likely to play 
a role in what works best for an individual patient. Overall, exer-
cise programs are more effective if supervised, often by physical 
therapists and sometimes in a class setting, rather than when 
performed by the individual at home. They also tend to be more 
effective when combined with self- efficacy and self- management 
interventions or weight loss programs.
Few studies have employed monitoring devices or pre- and 
postintervention assessment of cardiovascular or musculoskeletal 
fitness, so targets using these devices or assessments are not 
available. Future research is essential to establish specific exercise 
guidelines that will direct the patient and provider toward more 
individualized exercise prescriptions.
Balance exercises are conditionally recommended for 
patients with knee and/or hip OA.
Balance exercises include those that improve the ability to 
control and stabilize body position (American Physical Therapy 
Association: http://www.apta.org/Balan ceFal ls/). Although one 
might expect balance exercises to help reduce the risk of falls in 
patients with OA, RCTs to date have not addressed this outcome 
in this population, and the low quality of evidence addressing the 
use of balance exercises necessitates only a conditional recom-
mendation for balance exercises.
Weight loss is strongly recommended for patients with 
knee and/or hip OA who are overweight or obese.
A dose- response has been noted with regard to the amount 
of weight loss that will result in symptom or functional  improvement 
in patients with OA (18). A loss of ≥5% of body weight can be 
associated with changes in clinical and mechanistic outcomes. 
Furthermore, clinically important benefits continue to increase with 
weight loss of 5–10%, 10–20%, and >20% of body weight. The 
efficacy of weight loss for OA symptom management is enhanced 
by use of a concomitant exercise program.
Self-efficacy and self-management programs are strongly 
recommended for patients with knee, hip, and/or hand OA.
Although effect sizes are generally small, the benefits of 
participation in self- efficacy and self- management programs are 
consistent across studies, and risks are minimal. These programs 
use a multidisciplinary group–based format combining sessions 
on skill- building (goal- setting, problem- solving, positive thinking), 
education about the disease and about medication effects and 
side effects, joint protection measures, and fitness and exercise 
goals and approaches. Health educators, National Commission 
for Certification Services–certified fitness instructors, nurses, 
physical therapists, occupational therapists, physicians, and 
patient peers may lead the sessions, which can be held in person 
or online. In the studies reviewed, sessions generally occurred 3 
times weekly, but varied from 2 to 6 times weekly.
Tai chi is strongly recommended for patients with knee 
and/or hip OA.
Tai chi is a traditional Chinese mind- body practice that com-
bines meditation with slow, gentle, graceful movements, deep 
 diaphragmatic breathing, and relaxation. The efficacy of tai chi may 
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reflect the holistic impact of this mind- body practice on strength, 
balance, and fall prevention, as well as on depression and self- 
efficacy.
Yoga is conditionally recommended for patients with 
knee OA.
Yoga is a mind- body practice with origins in ancient Indian 
philosophy and typically combines physical postures, breath-
ing tech niques, and meditation or relaxation (National Center for 
Complementary and Integrative Health [NCCIH]: https ://nccih. 
nih.gov/healt h/yoga). Though far less well studied than tai chi, 
yoga may be helpful in OA through a similar blend of physical and 
psychosocial factors. Due to lack of data, no recommendation 
can be made regarding use of yoga to help manage symptoms 
of hip OA. Other mind- body practices could not be assessed due 
to insufficient evidence, as well as a lack of standard definitions of 
certain interventions (hypnosis, qi gong).
Cognitive behavioral therapy (CBT) is conditionally 
 recommended for patients with knee, hip, and/or hand OA.
There is a well- established body of literature (19,20) sup-
porting the use of CBT in chronic pain conditions, and CBT 
may have relevance for the management of OA. Trials have 
demonstrated improvement in pain, health- related quality of life, 
negative mood, fatigue, functional capacity, and disability in con-
ditions other than OA. In OA, limited evidence suggests that CBT 
may reduce pain (21). Further research is needed to establish 
whether or not benefits in OA are related to alteration in mood, 
sleep, coping, or other factors that may co- occur with, result 
from, or be a part of the experience of OA (22).
Cane use is strongly recommended for patients with 
knee and/or hip OA in whom disease in 1 or more joints 
is causing a sufficiently large impact on ambulation, joint 
 stability, or pain to warrant use of an assistive device.
Tibiofemoral knee braces are strongly recommended for 
patients with knee OA in whom disease in 1 or both knees is 
causing a sufficiently large impact on ambulation, joint sta-
bility, or pain to warrant use of an assistive device, and who 
are able to tolerate the associated inconvenience and burden 
associated with bracing.
Patellofemoral braces are conditionally recommended for 
patients with patellofemoral knee OA in whom disease in 1 or 
both knees is causing a sufficiently large impact on ambula-
tion, joint stability, or pain to warrant use of an assistive device.
The recommendation is conditional due to the variability in 
results across published trials and the difficulty some patients will 
have in tolerating the inconvenience and burden of these braces. 
Optimal management with knee bracing is likely to require that cli-
nicians are familiar with the various types of braces and where 
they are available and have expertise in fitting the braces. Patient 
Voting Panel members strongly emphasized the importance of 
coordination of care between primary care providers, specialists, 
and providers of braces.
Kinesiotaping is conditionally recommended for patients 
with knee and/or first CMC joint OA.
Kinesiotaping permits range of motion of the joint to which 
it is applied, in contrast to a brace, which maintains the joint in a 
fixed position. Published studies have examined various products 
and methods of application, and blinding with regard to use is not 
possible, thereby limiting the quality of the evidence.
Hand orthoses are strongly recommended for patients 
with first CMC joint OA.
Hand orthoses are conditionally recommended for pa-
tients with OA in other joints of the hand.
A variety of mechanical supports are available, including 
digital orthoses, ring splints, and rigid or neoprene orthoses, 
some of which are intended for specifically affected joints (e.g., 
first CMC joint, individual digits, wrist) and some of which sup-
port the entire hand. In addition, gloves may offer benefit by 
providing warmth and compression to the joints of the hand. 
Data are insufficient to recommend one type of orthosis over 
another for use in the hand. Patients considering these inter-
ventions will likely benefit from evaluation by an occupational 
therapist.
Modified shoes are conditionally recommended against 
in patients with knee and/or hip OA.
Modifications to shoes can be intended to alter the bio-
mechanics of the lower extremities and the gait. While optimal 
footwear is likely to be of considerable importance for those 
with knee and/or hip OA, the available studies do not define the 
best type of footwear to improve specific outcomes for knee or 
hip OA.
Lateral and medial wedged insoles are conditionally rec-
ommended against in patients with knee and/or hip OA.
The currently available literature does not demonstrate clear 
efficacy of lateral or medial wedged insoles.
Acupuncture is conditionally recommended for patients 
with knee, hip, and/or hand OA.
Although a large number of trials have addressed the use of 
acupuncture for OA, its efficacy remains a subject of controversy. 
Issues related to the use of appropriate blinding, the validity of 
sham controls, sample size, effect size, and prior expectations 
have arisen with regard to this literature. Variability in the results 
of RCTs and meta- analyses is likely driven, in part, by differ-
ences in the type of controls and the intensity of the control 
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interventions used. In addition, the benefits of acupuncture 
result from the large contextual effect plus small differences in 
outcomes between “true” and “sham” acupuncture. The latter 
is of the same magnitude as the effect of full- dose acetami-
nophen versus placebo. The greatest number of positive trials 
with the largest effect sizes have been carried out in knee OA. 
Positive trials and meta- analyses have also been published 
in a variety of other painful conditions and have indicated 
that acupuncture is effective for analgesia. While the “true” 
magnitude of effect is difficult to discern, the risk of harm is 
minor, resulting in the Voting Panel providing a conditional 
 recommendation.
Thermal interventions (locally applied heat or cold) are 
conditionally recommended for patients with knee, hip, and/
or hand OA.
The method of delivery of thermal interventions varies 
considerably in published reports, including moist heat, dia-
thermy (electrically delivered heat), ultrasound, and hot and 
cold packs. Studies using diathermy or ultrasound were more 
likely to be sham controlled than those using other heat delivery 
modalities. The heterogeneity of modalities and short duration 
of benefit for these interventions led to the conditional recom-
mendation.
Paraffin, an additional method of heat therapy for the 
hands, is conditionally recommended for patients with hand 
OA.
Radiofrequency ablation is conditionally recommended 
for patients with knee OA.
A number of studies have demonstrated potential analgesic 
benefits with various ablation techniques but, because of the het-
erogeneity of techniques and controls used and lack of long- term 
safety data, this recommendation is conditional.
Massage therapy is conditionally recommended against 
in patients with knee and/or hip OA.
Massage therapy encompasses a number of techniques 
aimed at affecting muscle and other soft tissue (NCCIH: 
https ://nccih.nih.gov/healt h/massa ge/massa geint roduc tion.
htm#hed2). Studies addressing massage have suffered from 
high risk of bias, have included small numbers of patients, 
and have not demonstrated benefit for OA- specific outcomes. 
Patient participants on the Patient and Voting Panels noted 
that some studies have shown positive outcomes and minimal 
risk and felt strongly that massage therapy was beneficial for 
symptom management (23). However, based on the available 
evidence regarding OA specifically, a conditional recommenda-
tion against the use of massage for reduction of OA symptoms 
is made, though the Voting Panel acknowledged that massage 
may have other benefits.
Manual therapy with exercise is conditionally recom-
mended against over exercise alone in patients with knee 
and/or hip OA.
Manual therapy techniques may include manual lymphatic 
drainage, manual traction, massage, mobilization/manipulation, 
and passive range of motion and are always used in conjunction 
with exercise (http://guide toptp racti ce.apta.org/conte nt/1/SEC38.
extract). A limited number of studies have addressed manual ther-
apy added to exercise versus exercise alone in hip and knee OA. 
Although manual therapy can be of benefit for certain conditions, 
such as chronic low back pain, limited data in OA show little addi-
tional benefit over exercise alone for managing OA symptoms.
Iontophoresis is conditionally recommended against in 
patients with first CMC joint OA.
There are no published RCTs evaluating iontophoresis for OA 
in any anatomic location.
Pulsed vibration therapy is conditionally recommended 
against in patients with knee OA.
Few trials have addressed pulsed vibration therapy, and 
in the absence of adequate data, we conditionally recommend 
against its use.
Transcutaneous electrical stimulation (TENS) is strongly 
recommended against in patients with knee and/or hip OA.
Studies examining the use of TENS have been of low quality 
with small size and variable controls, making comparisons across 
trials difficult. Studies have demonstrated a lack of benefit for knee 
OA.
Pharmacologic management (Table 2)
RCTs of pharmacologic agents may be subject to a variety 
of limitations, including generalizability of their findings across 
patients. Publication bias may reduce the likelihood that negative 
trials will become part of the published literature. Statistically sig-
nificant findings may represent benefits so small that they are not 
clinically important to patients. We have highlighted these consid-
erations where relevant.
Topical NSAIDs are strongly recommended for patients 
with knee OA and conditionally recommended for patients 
with hand OA.
In keeping with the principle that medications with the 
least systemic exposure (i.e., local therapy) are preferable, 
topical NSAIDs should be considered prior to use of oral 
NSAIDs (24). Practical considerations (e.g., frequent hand 
washing) and the lack of direct evidence of efficacy in the 
hand lead to a conditional recommendation for use of topical 
NSAIDs in hand OA. In hip OA, the depth of the joint beneath 
the skin surface suggests that topical NSAIDs are unlikely to 
ACR/AF GUIDELINE FOR MANAGEMENT OF HAND, HIP, AND KNEE OA |      157
confer benefit, and thus, the Voting Panel did not examine 
use in hip OA.
Topical capsaicin is conditionally recommended for 
patients with knee OA and conditionally recommended 
against in patients with hand OA.
Topical capsaicin is conditionally recommended for treat-
ment of knee OA due to small effect sizes and wide confidence 
intervals in the available literature. We conditionally recommend 
against the use of topical capsaicin in hand OA because of a 
lack of direct evidence to support use, as well as a potentially 
increased risk of contamination of the eye with use of topical 
capsaicin to treat hand OA. In hip OA, the depth of the joint 
beneath the skin surface suggests that topical capsaicin is 
unlikely to have a meaningful effect, and thus, the Voting Panel 
did not examine use of topical capsaicin in hip OA. Insufficient 
data exists to make recommendations about the use of topical 
lidocaine preparations in OA.
Oral NSAIDs are strongly recommended for patients with 
knee, hip, and/or hand OA.
Oral NSAIDs remain the mainstay of the pharmacologic man-
agement of OA, and their use is strongly recommended. A large 
number of trials have established their short- term efficacy. Oral 
NSAIDs are the initial oral medication of choice in the treatment of 
OA, regardless of anatomic location, and are recommended over 
all other available oral medications.
While this guideline did not address the relative merits of dif-
ferent NSAIDs, there is evidence suggesting that certain agents 
may have more favorable side effect profiles than others (25–27). 
Clinical considerations aimed at risk mitigation for the safe use of 
NSAIDs, such as appropriate patient selection, regular monitoring 
for the development of potential adverse gastrointestinal, cardio-
vascular, and renal side effects and potential drug interactions, were 
not specifically included in the GRADE process for the formulation of 
recommendations. Doses should be as low as possible, and NSAID 
treatment should be continued for as short a time as possible.
Intraarticular glucocorticoid injections are strongly rec-
ommended for patients with knee and/or hip OA and condi-
tionally recommended for patients with hand OA.
Trials of intraarticular glucocorticoid injections have demon-
strated short- term efficacy in knee OA. Intraarticular glucocorti-
coid injection is conditionally, rather than strongly, recommended 
for hand OA given the lack of evidence specific to this anatomic 
 location. There are insufficient data to judge the choice of short- 
acting over long- acting preparations or the use of low rather than 
high doses. A recent report (28) raised the possibility that specific 
steroid preparations or a certain frequency of steroid injections 
may contribute to cartilage loss, but the Voting Panel was uncer-
tain of the clinical significance of this finding, particularly since 
Table 2. Recommendations for the pharmacologic management of osteoarthritis of the hand, knee, and hip
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change in cartilage thickness was not associated with a worsen-
ing in pain, functioning, or other radiographic features.
Ultrasound guidance for intraarticular glucocorticoid 
injection is strongly recommended for injection into hip joints.
When available, ultrasound guidance for steroid injection 
may help ensure accurate drug delivery into the joint, but is not 
required for knee and hand joints. However, imaging guidance for 
injection into hip joints is strongly recommended.
Intraarticular glucocorticoid injections versus other injec-
tions are conditionally recommended for patients with knee, 
hip, and/or hand OA.
In OA generally, intraarticular glucocorticoid injection is con-
ditionally recommended over other forms of intraarticular injection, 
including hyaluronic acid preparations. Head- to- head compari-
sons are few, but the evidence for efficacy of glucocorticoid injec-
tions is of considerably higher quality than that for other agents.
Acetaminophen is conditionally recommended for patients 
with knee, hip, and/or hand OA.
In clinical trials, the effect sizes for acetaminophen are very small, 
suggesting that few of those treated experience important benefit, 
and meta- analysis has suggested that use of acetamin ophen as 
monotherapy may be ineffective (29). Longer- term treatment is no 
better than treatment with placebo for most individuals. Members 
of the Patient Panel noted that, for most individuals, acetaminophen 
is ineffective. For those with limited pharmacologic options due to 
intolerance of or contraindications to the use of NSAIDs, acetami-
nophen may be appropriate for short- term and episodic use. Regu-
lar monitoring for hepatotoxicity is required for patients who receive 
acetaminophen on a regular basis, particularly at the recommended 
maximum dosage of 3 gm daily in divided doses.
Duloxetine is conditionally recommended for patients 
with knee, hip, and/or hand OA.
While studied primarily in the knee, the effects of duloxetine 
may plausibly be expected to be similar for OA of the hip or hand. 
While a variety of centrally acting agents (e.g., pregabalin, gab-
apentin, selective serotonin reuptake inhibitors, serotonin norepi-
nephrine reuptake inhibitors, and tricyclic antidepressants) have 
been used in the management of chronic pain, only duloxetine has 
adequate evidence on which to base recommendations for use 
in OA. However, in considering all the ways in which OA may be 
affecting an individual patient, shared decision-making between 
the physician and patient may include consideration of any of 
these agents. Considering the utility of these agents in pain man-
agement generally, their use may be an appropriate target of future 
investigations specific to OA. Evidence suggests that duloxetine 
has efficacy in the treatment of OA when used alone or in combi-
nation with NSAIDs; however, there are issues regarding tolerabil-
ity and side effects. No recommendations were made for the other 
centrally acting agents due to lack of direct studies of relevance 
in OA.
Tramadol is conditionally recommended for patients with 
knee, hip, and/or OA.
Recent work has highlighted the very modest level of ben-
eficial effects in the long- term (3 months to 1 year) management 
of non- cancer pain with opioids (30). Nonetheless, there are cir-
cumstances in which tramadol or other opioids may be appropriate 
in the treatment of OA, including when patients may have con-
traindications to NSAIDs, find other therapies ineffective, or have 
no available surgical options. Patient Panel input demonstrated 
a high level of understanding concerning addiction potential, but 
also included an appreciation for the role of these agents when 
other pharmacologic and physical options have been ineffective. 
However, RCT evidence addressing the use of tramadol and other 
opioids for periods longer than 1 year is not available. Clinical trials 
have demonstrated some symptomatic efficacy, though concerns 
regarding potential adverse effects remain. If an opioid is being 
considered, tramadol is conditionally recommended over non- 
tramadol opioids.
Non-tramadol opioids are conditionally recommended 
against in patients with knee, hand, and/or hip OA with the 
recognition that they may be used under certain circum-
stances, particularly when alternatives have been exhausted.
As noted above, evidence suggests very modest benefits of 
long- term opioid therapy and a high risk of toxicity and depen-
dence. Use of the lowest possible doses for the shortest possible 
length of time is prudent, particularly since a recent systematic 
review and meta- analysis suggests that less pain relief occurs dur-
ing longer trials in the treatment of non- cancer chronic pain (30).
Colchicine is conditionally recommended against in 
patients with knee, hip, and/or hand OA.
Two very small studies have suggested analgesic benefit of 
colchicine in OA, but the quality of the data was low. In addition, 
potential adverse effects, as well as drug interactions, may occur 
with use of colchicine.
Fish oil is conditionally recommended against in patients 
with knee, hip, and/or hand OA.
Fish oil is the most commonly used dietary supplement in the 
US (31). Despite its popularity, only 1 published trial has addressed 
its potential role in OA. This study failed to show  efficacy of a 
higher dose of fish oil over a lower dose.
Vitamin D is conditionally recommended against in 
patients with knee, hip, and/or hand OA.
A number of trials in OA demonstrated small effect sizes 
with vitamin D treatment, while others have shown no benefit and 
 pooling data across studies yielded null results. In addition, limited 
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and questionable health benefits from vitamin D supplementation 
have been suggested in other contexts (32,33).
Bisphosphonates are strongly recommended against in 
patients with knee, hip, and/or hand OA.
Though a single small study of an oral bisphosphonate sug-
gested a potential analgesic benefit in OA, the preponderance of 
data shows no improvement in pain or functional outcomes.
Glucosamine is strongly recommended against in pa-
tients with knee, hip, and/or hand OA.
Pharmaceutical- grade preparations of glucosamine are 
available and have been studied in multiple trials. However, 
discrepancies in efficacy reported in studies that were industry 
sponsored as opposed to publicly funded have raised serious 
concerns about publication bias (34,35). In addition, there is 
a lack of a clear biologic understanding of how efficacy would 
vary with the type of salt studied. The data that were deemed to 
have the lowest risk of bias fail to show any important benefits 
over placebo. These recommendations represent a change from 
the prior conditional recommendation against the use of glu-
cosamine. The weight of the evidence indicates a lack of efficacy 
and large placebo effects. Nonetheless, glucosamine remains 
among the most commonly used dietary supplements in the 
US (31), and clinicians should be aware that many patients per-
ceive that glucosamine is efficacious. Patients also often perceive 
that different glucosamine formulas are associated with different 
degrees of efficacy and seek advice on brands and manufactur-
ers. The potential toxicity of glucosamine is low, though some 
patients exposed to glucosamine may show elevations in serum 
glucose levels (36).
Chondroitin sulfate is strongly recommended against in 
patients with knee and/or hip OA as are combination prod-
ucts that include glucosamine and chondroitin sulfate, but is 
conditionally recommended for patients with hand OA.
A single trial suggested analgesic efficacy of chondroitin sul-
fate, without evidence of harm, in hand OA.
Hydroxychloroquine is strongly recommended against in 
patients with knee, hip, and/or hand OA.
Well- designed RCTs of hydroxychloroquine, conducted in 
the subset of patients with erosive hand OA, have demonstrated 
no efficacy.
Methotrexate is strongly recommended against in pa-
tients with knee, hip, and/or hand OA.
Well- designed RCTs of methotrexate, conducted in the subset 
of patients with erosive hand OA, have demonstrated no  efficacy.
Intraarticular hyaluronic acid injections are conditionally 
recommended against in patients with knee and/or first CMC 
joint OA and strongly recommended against in patients with 
hip OA.
In prior systematic reviews, apparent benefits of hyaluronic 
acid injections in OA have been reported. These reviews have not, 
however, taken into account the risk of bias of the individual pri-
mary studies. Our review showed that benefit was restricted to 
the studies with higher risk of bias: when limited to trials with low 
risk of bias, meta- analysis has shown that the effect size of hyal-
uronic acid injections compared to saline injections approaches 
zero (37). The finding that best evidence fails to establish a benefit, 
and that harm may be associated with these injections, motivated 
the recommendation against use of this treatment.
Many providers want the option of using hyaluronic acid injec-
tions when glucocorticoid injections or other interventions fail to 
adequately control local joint symptoms. In clinical practice, the 
choice to use hyaluronic acid injections in the knee OA patient who 
has had an inadequate response to nonpharmacologic therapies, 
topical and oral NSAIDs, and intraarticular steroids may be viewed 
more favorably than offering no intervention, particularly given the 
impact of the contextual effects of intraarticular hyaluronic acid 
injections (38). The conditional recommendation against is con-
sistent with the use of hyaluronic acid injections, in the context 
of shared decision- making that recognizes the limited evidence 
of benefit of this treatment, when other alternatives have been 
exhausted or failed to provide satisfactory benefit. The conditional 
recommendation against is not intended to influence insurance 
coverage decisions.
In contrast, the evidence of lack of benefit is of higher 
quality with respect to hyaluronic acid injection in the hip. We 
therefore strongly recommend against hyaluronic acid injec-
tions in hip OA.
Intraarticular botulinum toxin injections are conditionally 
recommended against in patients with knee and/or hip OA.
The small number of trials of intraarticular botulinum toxin 
treatment in knee or hip OA suggest a lack of efficacy. This treat-
ment has not been evaluated in hand OA and, therefore, no 
 recommendation is made with regard to OA of the hand.
Prolotherapy is conditionally recommended against in 
patients with knee and/or hip OA.
A limited number of trials involving a small number of partici-
pants have shown small effect sizes of prolotherapy in knee or hip 
OA. However, injection schedules, injection sites, and compara-
tors have varied substantially between trials. This treatment has 
not been evaluated in hand OA and, therefore, no recommenda-
tion is made with regard to OA of the hand.
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Platelet-rich plasma treatment is strongly recommended 
against in patients with knee and/or hip OA.
In contrast to intraarticular therapies discussed above, there is 
concern regarding the heterogeneity and lack of standardization in 
available preparations of platelet- rich plasma, as well as techniques 
used, making it difficult to identify exactly what is being injected. 
This treatment has not been evaluated in hand OA and, therefore, 
no recommendation is made with regard to OA of the hand.
Stem cell injections are strongly recommended against 
in patients with knee and/or hip OA.
There is concern regarding the heterogeneity and lack of 
standardization in available preparations of stem cell injections, as 
well as techniques used. This treatment has not been evaluated in 
hand OA and, therefore, no recommendation is made with regard 
to OA of the hand.
Tumor necrosis factor inhibitors and interleukin-1 recep-
tor antagonists are strongly recommended against in patients 
with knee, hip, and/or hand OA.
Tumor necrosis factor inhibitors and interleukin- 1 receptor 
antagonists have been studied in trials using both subcutaneous 
and intraarticular routes of administration. Efficacy has not been 
demonstrated, including in erosive hand OA. Therefore, given their 
known risks of toxicity, we strongly recommended against their 
use for any form of OA.
Initial observations addressing the use of anti–nerve growth 
factor (anti- NGF) agents suggest that significant analgesic benefits 
may occur but that incompletely explained important safety issues 
may arise. A small subset of patients treated with these agents 
had rapid joint destruction leading to early joint replacement. The 
FDA temporarily halted clinical trials of anti- NGF as a result, but 
trials have since resumed, with ongoing collection of longer- term 
efficacy and safety data. As none of these agents were approved 
for use by the FDA and the longer- term data were not available at 
the time of the literature review and Voting Panel meeting, we are 
unable to make recommendations regarding the use of anti- NGF 
therapy.
DISCUSSION
These 2019 ACR/AF recommendations for the manage-
ment of OA are based on the best available evidence of ben-
efit, safety, and tolerability of physical, educational, behavioral, 
psychosocial, mind- body, and pharmacologic interventions, as 
well as the consensus judgment of clinical experts. The GRADE 
approach used provided a comprehensive, explicit, and trans-
parent methodology for developing recommendations for OA 
management. The choice of any single or group of interventions 
may vary over the course of the disease or with patient and 
provider preferences, and is optimally arrived at through shared 
decision- making.
The Voting Panel made strong recommendations for patients 
to participate in a regular, ongoing exercise program. The litera-
ture provides support for choice from a broad menu of exercises 
for patients with OA. The effectiveness of an exercise program 
is enhanced when patient preferences and access to exercise 
programs are considered, as well as when they are supervised 
or coupled with self- efficacy, self- management, and weight loss 
programs. Strong recommendations were also made for weight 
loss in patients with knee and/or hip OA who are overweight 
or obese, self- efficacy and self- management programs, tai chi, 
cane use, first CMC joint orthoses, tibiofemoral bracing, topical 
NSAIDs for knee OA and oral NSAIDs for hand, knee, and/or 
hip OA, and intraarticular glucocorticoid injections for knee and/
or hip OA. The Voting Panel made conditional recommenda-
tions for balance exercises, yoga, CBT, kinesiotaping, orthoses 
for hand joints other than the first CMC, patellofemoral bracing, 
acupuncture, thermal modalities, radiofrequency ablation, topical 
NSAIDs, intraarticular steroid injections and chondroitin sulfate for 
hand OA, topical capsaicin for knee OA, acetaminophen, dulox-
etine, and tramadol. The recommendations provide an array of 
options for a comprehensive approach for optimal management 
of OA encompassing the use of educational, physical, behavioral, 
psychosocial, mind- body, and pharmacologic interventions. The 
availability, accessibility, and affordability of some of these inter-
ventions vary, but in many communities the AF, as well as local 
hospitals and other health- related agencies, offer free self- efficacy 
and self- management programs.
For some patients with more limited disease in whom med-
ication is required, topical NSAIDs represent an appropriate first 
choice. For others, particularly with hip OA or polyarticular involve-
ment, oral NSAIDs are more appropriate. The appropriate use of 
other oral agents, particularly acetaminophen and opioids, will 
continue to evolve (39–41).
Despite the many options available, some patients may con-
tinue to experience inadequate symptom control; others will expe-
rience adverse effects from the available interventions. Clinicians 
treating patients in these circumstances should choose interven-
tions with a low risk of harm, but both clinicians and patients may be 
dissatisfied with the options and unsure of how to choose among 
them. There are controversies in interpretation of the evidence, 
particularly with regard to the use of glucosamine and chondroitin, 
acupuncture, and intraarticular hyaluronic acid injections. Nonethe-
less, the process of updating treatment guidelines permits scrutiny 
of the state of the literature and identification of critical gaps in our 
knowledge about best practices. Further, it highlights the need for 
ongoing, appropriately funded,  high- quality clinical research, as 
well as development of new treatment  modalities, to address the 
human and economic impact of the most common form of arthritis.
No effective disease- modifying agents for OA have yet been 
identified though phase 2 and 3 trials are underway, and, for the 
time being, preventive strategies focus on weight management 
and injury prevention. Development of more effective therapies that 
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permit a sophisticated and individualized approach to the patient 
with OA await the outcome of future investigation. Important direc-
tions for research include gaining a more comprehensive under-
standing of the optimal types of exercises and the modifications that 
should be used based on disease location and severity, study of 
the intensity of exercise that would be optimal for a given individual 
(https ://health.gov/pagui delin es/second-editi on/report.aspx), defin-
ing optimal footwear for patients with knee and hip OA and under-
standing the interaction between footwear and exercise, conducting 
rigorous RCTs for physical modality options in hand OA, assessing 
a broader array of outcomes, including fall prevention, assessing 
optimal use of oral, topical, and injectable agents alone and in com-
bination, obtaining a better understanding of the role of integrative 
medicine, including massage, herbal products, medical marijuana, 
and additional mind- body interventions, and exploring agents with 
novel mechanisms of action for prevention and treatment.
In conclusion, optimal management requires a comprehen-
sive, multimodal approach to treating patients with hand, hip, and/
or knee OA offered in the context of shared decision- making with 
patients, to choose the safest and most effective treatment pos-
sible. A large research agenda remains to be addressed, with a 
need for more options with greater efficacy for the millions of peo-
ple worldwide with osteoarthritis.
Addendum. Therapies that were approved after the 
original systematic literature review are not included in these 
 recommendations.
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